As a new type of foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply dimethylsilicone oil sourced directly from multiple well-known original manufacturers. With over a decade of market experience as a tech-driven foreign trade enterprise supported by technological transformation cooperation with manufacturers, HiSiaddi boasts extensive experience resolving product compliance issues. Below is a case addressing dimethylsilicone oil compliance challenges delivered by HiSiaddi.
For inquiries about dimethylsilicone oil product compliance issues, please contact HiSiaddi customer service.
Sofipharm of France is located in the Lyon Biomedical Industrial Park, a leading local mid-to-high-end manufacturer of prescription pharmaceuticals and dietary supplements specializing in pharmaceutical soft capsules, topical ointments and probiotic oral liquids. Its full product line complies with four major access specifications: European Pharmacopoeia EP10.0, EU Food Regulation EC1935/2004, REACH (EU2024/1328) new regulation and French AFNOR food contact standards. The enterprise has long sourced Wacker Germany’s pharmaceutical grade dimethylsilicone oil for soft capsule mold demolding, liquid medicine fermentation defoaming and topical ointment substrates, with an annual procurement demand of 242 tons. Faced with production capacity maintenance shutdowns at European local silicon chemical manufacturers, a continuous 42% surge in imported raw material pricing and extended delivery lead times of up to 120 days, the enterprise launched a China localization substitution procurement project in 2025. It initially selected a domestic silicone oil manufacturer to purchase 80 tons of pharmaceutical grade dimethylsilicone oil, yet prior to shipment after production completion, internal compliance laboratory sampling by the French client identified four fatal compliance defects, risking full-container detention and forced return shipment. Restoring original European imported silicone oil would trigger a 28-day production line shutdown, directly causing over one million Euros in production losses. After unsuccessful rectification coordination with the original manufacturer, the client fully entrusted HiSiaddi’s domestic chemical foreign trade team to coordinate full-process compliance rectification, raw material process optimization, complete supporting compliance documentation preparation and re-shipping implementation.
Four core compliance barriers exposed by client testing, the primary obstacles blocking product entry into the EU market:
1. Non-compliance with REACH environmental regulations: Excessive D4/D5 cyclic siloxane residues: Total D4+D5 cyclic siloxane content of finished dimethylsilicone oil reached 1280ppm (0.128%), exceeding the mandatory EU REACH new regulation limit of ≤1000ppm (0.1%). D4 and D5 are listed on the SVHC Substances of Very High Concern inventory; products exceeding limits are prohibited from circulation within EU territory, with French customs imposing full-container detention and forced return upon detection. The original manufacturer only adopted simple atmospheric devolatilization without molecular distillation refining procedures, unable to deeply remove cyclic siloxane by-products.
2. Mismatched pharmaceutical qualifications and missing EP Pharmacopoeia supporting compliance documentation: The manufacturer only provided domestic food production qualifications, unable to issue EP Pharmacopoeia-compliant COA test reports and LFGB food contact migration test reports. French drug regulatory warehouse access audits require raw materials to be accompanied by full pharmacopoeia test data; missing documentation disqualifies raw materials from warehouse filing and preparation production deployment.
3. SDS safety data sheets inconsistent with updated EU specifications: The manufacturer’s original MSDS adopted outdated domestic formats without updated SVHC hazardous substance labeling, missing SCIP database filing information, and using national standard indicators for physical and chemical parameters and toxicological data, violating EU CLP classification and labeling regulations that risk customs refusal of release at destination ports.
4. Excessive heavy metal and trace impurity compliance levels: Total lead, arsenic and cadmium heavy metal content reached 1.42ppm, exceeding the EP Pharmacopoeia control standard of ≤1ppm, posing human safety risks for oral soft capsules and topical pharmaceutical ointments and violating mandatory French drug regulatory raw material access requirements.
The original supplier manufacturer only produces goods per domestic national standards, lacking experience rectifying compliance for EU market access and refined production equipment, refusing high-cost production line renovation and insisting delivery compliance upon meeting domestic national standards, declining to optimize processes or complete supplementary compliance documentation, trapping the client in a passive predicament of scrapped goods and imminent production shutdown.
HiSiaddi assembled a special cross-functional team integrating chemical technical specialists, compliance certification experts and customs clearance specialists, implementing rectification item by item across four dimensions – raw material production process optimization → third-party compliance testing → complete documentation preparation → packaging and labeling compliance upgrades – in accordance with the client’s French regulatory checklist and current EU REACH and EP Pharmacopoeia provisions, closing the full compliance loop within 46 days while submitting French-language progress reports to the client’s French compliance and R&D departments throughout the process.
HiSiaddi terminated supply from the non-compliant original manufacturer and selected a premium domestic silicon enterprise with pharmaceutical silicone oil clean production lines, two-stage short-path molecular distillation and hydrofining equipment (Xinyaqiang Pharmaceutical Silicone Division) for re-customized production aligned with European Pharmacopoeia standards, implementing targeted process optimizations:
1. High-purity closed-loop D3 monomers replaced industrial mixed DMC feedstock to reduce cyclic siloxane by-product generation at the source. Segmented temperature-controlled polymerization precisely locked molecular polymerization degrees; post-synthesis materials entered two-stage negative-pressure molecular distillation units to remove small-molecule D4 and D5 cyclic siloxanes in segmented vacuum processes, controlling total finished product D4+D5 residues at 386ppm, far below the EU statutory 0.1% upper limit and fully eliminating REACH restricted substance compliance risks.
2. Activated carbon deep adsorption plus three-stage precision filtration procedures were added to remove trace heavy metals and catalyst residues retained from raw material polymerization, reducing total lead, arsenic and cadmium content to 0.65ppm to meet EP Pharmacopoeia heavy metal control limits. Full production occurred in Class 100,000 sealed clean workshops to eliminate cross-contamination from industrial-grade silicone oil and guarantee pharmaceutical raw material cleanliness compliance.
3. A low-temperature low-boiling point removal procedure was added for ointment-grade silicone oil to control volatile organic compound (VOC) levels, matching France’s environmental control requirements for cosmetic excipients.
1. HiSiaddi coordinated a CNAS-accredited third-party testing institution with EU laboratory mutually recognized test reports to conduct simultaneous testing of newly produced batches against three standards: full EP10 Pharmacopoeia indicators, German LFGB food contact migration standards and REACH hazardous substance screening. Testing covered 27 indicators including viscosity, refractive index, cyclic siloxane residues, heavy metals, microorganisms, skin irritation and food migration tests. After passing all tests, formal Chinese-English-French trilingual COA quality inspection reports and LFGB compliance test documents were issued, all traceable within EU drug regulatory systems to meet client warehouse filing audit requirements.
2. Manufacturers were assisted with REACH substance pre-registration filing for raw materials, completing SCIP database information submission for trace residual substances within products and supplementing SVHC compliance declaration documents to avoid EU environmental notification risks.
HiSiaddi compliance specialists discarded the manufacturer’s outdated domestic MSDS and recompiled English-French bilingual updated SDS safety data sheets aligned with EU CLP regulations and revised REACH bills:
1. Section 3 component information was refined to accurately label actual residual D4/D5 content and SVHC related substance information; supplementary data was added to Section 8 exposure controls, Section 11 toxicological data and Section 12 ecotoxicological parameters, all adopting EU standard test data.
2. Dual-signed DoC declarations of conformity (manufacturer + foreign trade enterprise signatures) were issued, clearly stating full compliance of products with applicable REACH, LFGB and EP regulations, a mandatory document for French importers to complete local EU compliance filing and resolve customs clearance documentation non-compliance risks.
1. IMDG maritime regulation compliant food-grade IBC tote tanks and sterile 25kg plastic drums replaced original packaging, with drum materials passing LFGB food contact testing to eliminate pollutant precipitation risks from packaging materials.
2. English-French bilingual product labels were reprinted per EU CLP labeling specifications, marking product CAS numbers, hazard classifications, storage conditions, importer information and compliance filing numbers to avoid port label inspection detention risks.
Rectified finalized samples were airfreighted to Sofipharm’s French compliance laboratory in separate batches, passing three rounds of full physical and chemical retesting, preparation compatibility small trials and ointment accelerated stability testing, with all product indicators fully matching original Wacker pharmaceutical grade dimethylsilicone oil performance. The client’s compliance department formally issued a product market access release confirmation letter. The rectified initial batch of 80 tons of goods was shipped in two containers from Shanghai Port to Le Havre Port, France. HiSiaddi submitted full compliance documentation (COA, LFGB test reports, updated SDS, DoC, REACH filing certificates) to the French customs broker for pre-review in advance, enabling one-time smooth customs clearance and inspection upon cargo arrival at the port without detention or sampling objections. Raw materials entered warehouses and successfully deployed on three preparation production lines, completely avoiding production shutdown losses.
The remaining 162 tons of annual ordered goods fully adopted the compliance grade and supporting compliance documentation standards finalized by HiSiaddi, shipped smoothly in five monthly batches, achieving 100% on-time delivery of the full 242-ton annual procurement order. Comprehensive localized procurement costs decreased by 35.7% compared to original Wacker products, ocean shipping lead times were compressed to 39 days, and the client’s comprehensive raw material production costs dropped by 21.3%.
In the following year, Sofipharm renewed its annual long-term supply contract for 310 tons of dimethylsilicone oil series, fully entrusting HiSiaddi with compliance audits, model selection and documentation agency services for all supporting silicon raw materials including emulsified silicone oil, pharmaceutical silicone waxes and modified antifoaming silicone oil. Leveraging this compliance implementation case, HiSiaddi successfully expanded organosilicon raw material export business with three additional equivalent mid-to-high-end food and pharmaceutical enterprises based in France.
1. Universal Industry Pain Points: Most domestic silicone oil manufacturers only produce goods aligned with Chinese national standards, lacking understanding of refined overseas compliance regulations including EU REACH, EP Pharmacopoeia and LFGB, and missing supporting molecular distillation and deep refining production equipment, only capable of manufacturing products meeting general domestic standards. Mid-to-high-end European pharmaceutical clients are bound by stringent EU drug regulatory and environmental laws, prioritizing raw material compliance above product pricing; any non-compliance in raw materials or documentation triggers full-batch return shipment risks and substantial production shutdown losses, with a single manufacturer unable to deliver full-chain services covering both production and cross-border compliance.
2. HiSiaddi’s Core Foreign Trade Service Value: Distinct from traditional middlemen solely engaged in source supply without compliance support, HiSiaddi delivers a closed-loop full-chain compliance service covering regulatory interpretation → raw material process rectification → third-party testing certification → documentation compilation → packaging and labeling optimization → destination port customs clearance pre-review through dual-dimensional capabilities integrating compliance expertise and technical support. It fills two-way information barriers: overseas clients lack familiarity with China’s production processes, while domestic manufacturers lack expertise in EU regulations, achieving deep binding with mid-to-high-end European and American pharmaceutical end users through value-added compliance services.
3. Procurement Logic of High-End Clients: During localized sourcing for European and American pharmaceutical mid-to-high-end enterprises, the primary demand is fully implementable full-chain product compliance, traceable complete documentation and controllable risks. The ability to deliver one-stop cross-border compliance resolution is the decisive factor for clients selecting foreign trade service providers and locking long-term cooperation.
For inquiries about dimethylsilicone oil product compliance issues, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
